The monoclonal antibody in development as maintenance therapy for people with moderately to severely active ulcerative colitis was more effective than placebo.
These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.
Psoriatic disease decision tree needed to match treatment choices with target domains healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes employed to evaluate change in axial symptoms.